Literature DB >> 34728470

Postdiagnosis BMI Change Is Associated with Non-Small Cell Lung Cancer Survival.

Qianyu Yuan1, Mulong Du1,2, Elizabeth Loehrer3, Bruce E Johnson4,5, Justin F Gainor6,7, Michael Lanuti6, Yi Li8, David C Christiani9,10.   

Abstract

BACKGROUND: Body mass index (BMI) change after a lung cancer diagnosis has been associated with non-small cell lung cancer (NSCLC) survival. This study aimed to quantify the association based on a large-scale observational study.
METHODS: Included in the study were 7,547 patients with NSCLC with prospectively collected BMI data from Massachusetts General Hospital and Brigham and Women's Hospital/Dana-Farber Cancer Institute. Cox proportional hazards regression with time-dependent covariates was used to estimate effect of time-varying postdiagnosis BMI change rate (% per month) on overall survival (OS), stratified by clinical subgroups. Spline analysis was conducted to quantify the nonlinear association. A Mendelian Randomization (MR) analysis with a total of 3,495 patients further validated the association.
RESULTS: There was a J-shape association between postdiagnosis BMI change and OS among patients with NSCLC. Specifically, a moderate BMI decrease [0.5-2.0; HR = 2.45; 95% confidence interval (CI), 2.25-2.67] and large BMI decrease (≥2.0; HR = 4.65; 95% CI, 4.15-5.20) were strongly associated with worse OS, whereas moderate weight gain (0.5-2.0) reduced the risk for mortality (HR = 0.78; 95% CI, 0.68-0.89) and large weight gain (≥2.0) slightly increased the risk of mortality without reaching statistical significance (HR = 1.10; 95% CI, 0.86-1.42). MR analyses supported the potential causal roles of postdiagnosis BMI change in survival.
CONCLUSIONS: This study indicates that BMI change after diagnosis was associated with mortality risk. IMPACT: Our findings, which reinforce the importance of postdiagnosis BMI surveillance, suggest that weight loss or large weight gain may be unwarranted. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34728470      PMCID: PMC8755617          DOI: 10.1158/1055-9965.EPI-21-0503

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  33 in total

1.  Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.

Authors:  Philip Bonomi; Marta Batus; Mary Jo Fidler; Jeffrey A Borgia
Journal:  Ann Transl Med       Date:  2017-03

2.  Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Authors:  Sandra Garcia; Ajit Bisen; Jingsheng Yan; Xian-Jin Xie; Suresh Ramalingam; Joan H Schiller; David H Johnson; David E Gerber
Journal:  J Thorac Oncol       Date:  2017-08-09       Impact factor: 15.609

Review 3.  Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications.

Authors:  Xueli Zhang; Yamin Liu; Hua Shao; Xiao Zheng
Journal:  J Thorac Oncol       Date:  2017-07-27       Impact factor: 15.609

4.  Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery.

Authors:  Tatsuo Nakagawa; Toshiya Toyazaki; Naohisa Chiba; Yuichiro Ueda; Masashi Gotoh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-05-31

Review 5.  Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis.

Authors:  Arjun Gupta; Kaustav Majumder; Nivedita Arora; Helen G Mayo; Preet Paul Singh; Muhammad S Beg; Randall Hughes; Siddharth Singh; David H Johnson
Journal:  Lung Cancer       Date:  2016-11-01       Impact factor: 5.705

6.  Weight change and survival after breast cancer in the after breast cancer pooling project.

Authors:  Bette J Caan; Marilyn L Kwan; Xiao Ou Shu; John P Pierce; Ruth E Patterson; Sarah J Nechuta; Elizabeth M Poole; Candyce H Kroenke; Erin K Weltzien; Shirley W Flatt; Charles P Quesenberry; Michelle D Holmes; Wendy Y Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-13       Impact factor: 4.254

7.  Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.

Authors:  Jack Bowden; George Davey Smith; Stephen Burgess
Journal:  Int J Epidemiol       Date:  2015-06-06       Impact factor: 7.196

8.  Post-diagnosis weight loss as a prognostic factor in non-small cell lung cancer.

Authors:  Daniel S Mytelka; Li Li; Karin Benoit
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-12-04       Impact factor: 12.910

9.  The MR-Base platform supports systematic causal inference across the human phenome.

Authors:  Gibran Hemani; Jie Zheng; Benjamin Elsworth; Tom R Gaunt; Philip C Haycock; Kaitlin H Wade; Valeriia Haberland; Denis Baird; Charles Laurin; Stephen Burgess; Jack Bowden; Ryan Langdon; Vanessa Y Tan; James Yarmolinsky; Hashem A Shihab; Nicholas J Timpson; David M Evans; Caroline Relton; Richard M Martin; George Davey Smith
Journal:  Elife       Date:  2018-05-30       Impact factor: 8.140

10.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator.

Authors:  Jack Bowden; George Davey Smith; Philip C Haycock; Stephen Burgess
Journal:  Genet Epidemiol       Date:  2016-04-07       Impact factor: 2.135

View more
  1 in total

1.  Sarcopenia defined by skeletal muscle mass index at the third lumbar vertebra is a prognostic factor for extensive-stage small cell lung cancer patients: a retrospective study.

Authors:  Kai Wang; Wen Long; Xiaoxian Sima; Yuanyuan Zhao; Bijing Xiao; Haimiti Gulizeba; Yan Huang
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.